Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
MM needs to walk this higher .. hard to rinse at these levels!
Yea crazy.. don't need money got enough!
Got burned on first R/S but second R/S gave me opportunity to load the boat low in subs. Always liked the drug platform "Cancer Grenade" and "deadly Carrot" catch phrases for a powerful cancer drug and the L&C drugs just added to the interest. Going to wait it out and see what happens. Not worried a bit about another R/S.
I like your patience to get filled.. big money moving into other tickers leaving NSPX behind for the time being. you are correct that without some news from the ticker a slide may be possible.. i've see it before! After last R/S with nothing positive to hold PPS up stock quickly slide to subs!
Silence for over 2 yrs dropped this ticker to sub pennies. Don't expect news until it actually hits. If you believe in the DD hold until or if something develops if not go elsewhere. It may not be a user friendly ride but the reward may be big if you have stamina!
Did you move your entry up today. Held support @.0125..may run up tomorrow so you could flip some! Easy Money!
Yes Mipsagargin locked up until 2034! no brainer! Think hard about it...and you'll do the right thing! lock and load!
Buy High Sell Low...favorite strategy on the OTC. Happens all day every day!
He's referring to the intangible assets in the Financial Information page 1 of the latest filing. 10-Q. Although he is technically correct.. that number is subjective and can escalate quickly with future events!
Try to get in touch with Chris Lowe (managing Partner). I've e-mailed him a few times in the past but never got a response.. maybe you'll have better luck. Since he took over in 2016 he was quiet.. never really communicate well with the shareholders!
Not alot of action at this level..MM may bid this up to get something going!
FLG and Chris Lowe were brought in by Genspera in march 2016 to replace failed founder and ceo Craig Dionne. In 3 yrs as ceo Lowe, changed the name to Inspyr, orchestrated 2 R/S, merged with L&C and subsequently closed down both Inspyr and L&C in march 2018. He stayed on as only employee until july 19 and then left and was replaced by interim ceo michael cain. Not a very dynamic tenure for Lowe and FLG at nspx! The PPS under his watch tells the whole story not me!
Chris Lowe NSPX ex ceo is a managing director of FLG. He resigned from NSPX in July 19. Currently I believe the relationship between FLG and NSPX is over however Chris Lowe is still listed as a board member of NSPX on FLG website.
NSPX is going to fly up and none of the pumps or bashes on this site will make a difference.. nor mine. It's completely out of the hands of penny stock self proclaimed experts! So don't waste your time trying to out think the future results!
hello
The FDA is a government agency that is loaded with bureaucracy and red tape. On the average it takes 12 years and $350 million to navigate a drug from the lab to the pharmacy shelf. It is controlled heavily by politicians that are indebted to BIG Pharma for donations. Since PH I study of G-202 (now mipsagargin) which began in 2010 60+ million has been spent. For some to insinuate that it is non-effective because it has not moved on to Ph III or a failed drug simply do not understand the process. Mipsagargin will be a powerful and effective tumor killer in many different applications.
So true... reviewing data and making a judgement that a stock will gain in value is the easy part..WHEN the factors are going to come together that release that value (timing) is the hard part.
Read 10-Q filing for period ending 9/30/19. Last 10-Q posted. Top of page 27 under risk factors.. " Our Therapeutic compounds ...etc. how do you interpret this?
YOU ARE CERTAINLY CORRECT. Mipsagargin has the potential to be the REAL game changer. The pro drug can be designed to attack other molecules other than PSMA and therefore be a cancer killer to other cancer types.. all with little or tolerable side effects. Also, it could be inject able so lengthy drip procedures at oncologist office or hospital would be eliminated. Phyton need to get a commercially and cost effective supply of thapsigargin and the game will change rapidly. Phyton did it with taxol and changed breast cancer treatment for years!
There is nothing wrong with NSPX licensing aspects of the adenosine drug platform to Ridegway even if it is only a marketing concern. The adenosine platform has already been thoroughly conceived and established as viable by L&C Pharma. With Hislop's USA and Euopean connections the chances of bringing a financial deal to both Ridgeway and therfore NSPX does nothing but improve.
To add to the conspiracy theory.. Ridgeway may be an agent for an England based pharmaceutical company. Colin Hislop who has been depicted as President and CEO of Ridgeway has a full time job as Senior V.P. at Eiger Bio-pharmaceuticals. He is from London and has specific ties to various US and European drug companies. It looks like Ridgeway may be trying to broker the NSPX drug platform to who ever has the cash to take it on. So far no takers. TOTALLY my Speculation and opinion.
Looks that way. Just following post #25356.. could be the home of owner of the owner of Ridgeway? Lots of owners list there home as office address.
Do you think it may be a coincidence that Conor Flannery office is 4085 Campbell ave MENLO PARK CA and Ridgeways HQ is at 785 Arbor Rd MENLO PARK CA....3.5 miles apart!
I have seen or heard nothing that the 5000 shares of preferred stock that he bought in jan 19 for $5000 has been converted to the 1,000,000 shares of common shares @.005. If he still owns the preferred stock it would be financially advantageous to him to convert his preferred stock at the highest PPS as possible!
It is known that NSPX has licensed ADENOSINE related compounds to Ridgeway Therapeutics. Ridgeway is a private company. There is no public information concerning the status of the work Ridgeway is doing or/if in fact they are doing anything. This association needs to play out and see where it goes if anywhere!
The spike in trading activity can be attributed to one word ADENOSINE! It is what links NSPX to Gileads remdesivir. The company has said nothing concerning COVID-19. The trading activity is the result of trader's imagination that something may develop from that association. In the mean time more eyes see the drugs and pipeline and patents that NSPX owns and this also has helped trading activity. Why would they issue a PR denying something that they never had part in doing?
In addition I believe his"blank check" preferred series D stock is convertible into 1,000,000 shares of common stock. So for 75K he got controlling interest of the company plus ability to wheel and deal as he sees fit (he has majority votes on issues) and when he wants to convert he gets 1,000,000 shares at market price. All my opinion.
A minor correction..each one of the preferred shares has 30,001 votes per share. Therefore is a proposal came up say another R/S and he was for it the yeas would be 150,005,000. And if all the common stockholders voted against the neas would be 150,000,000. (they wouldn't have to vote anyway because his preferred stock is always in the majority)
As I believe.. some time back Conor Flannery bought 5000 shares of series D preferred stock which gave him 30,000 votes per share= 150,000 voting rights. Rumors have circulated that he pd $75,000.00 for the preferred stock. With that purchase he took over controlling interest in the company on any decision that require shareholder approval since his 150,000 votes for or against any proposal would be the majority. He would have to OK any further R/S or increasing the A/S which now is 180,000 shares..150,000 common and 30,000 preferred shares. Anyone or any entity can buy up the common shares but they would still have to deal with him since he owns the preferred stock!
News will only come when it is SOLID news! NSPX will NOT PR anything for the sack of releasing something. It is possible/probable that the next we hear from the company is the delayed 10-K in mid may. Twitter will be active on retweets as it has been. This might have to trade on air as all anticipates what is coming. It probably won't go straight up and it probably will be bumpy but there is nothing wrong with a steady up trend.
Starting to look a lot like last year..the timing wasn't there then but as they say timing is everything.
Others have tried to contact him in relation to NSPX. Obviously, he is going to give zero information that is not within the public information spectrum if he even acknowledges the contact at all. Everyone is very tight liped concerning this ticker and has been for awhile. The most you can get from anyone refers you to the filings!
I don't think so.. closed tomorrow for sure but I could be wrong.
NSPX has never put out bogus PR to pump the ticker. They don't have to. There is a trove of solid information concerning what the stock has and the informed investor who is interested in what he/she is investing in can easily access!
Check out Connor Flannery managing director of JLL property management in San Francisco. At one time he owned the 5000 shares of Series D preferred stock.
I think the michael cain that is president of Level 4 services is the interim ceo. I may be wrong!
the filing in jan was 1,137,260 x 4= 4,549,040 shares. sabbies position has 4 different entities hold shares
This stock was formed in 2003 went public in 2009 and by spending 60 million and mergers now have the IP and patents they own. The science and platforms of the drugs were developed by renowned research scientists from the best research hospitals. The drugs are continued to be studied by various research institutions. All is open and can be verified. There is nothing fake or shams about NSPX. Various developments in the past have held the stock back (mainly a lack of commercial supply of mipsagargin) however the more eyes on this stock the more an intelligent valuation can be made. However, it is a penny stock and the trading will progress as penny stocks do on a daily basis. The risk is there but the reward is out there to be had. I'm not going to give away any of my shares!
Probably a financial decision on what patent applications to keep active and what ones to abandon. Like everything else in Bio world..patents cost a lot of money!
The merger with L&C took place in Sept 2017. When Chris Lowe stopped all operations in March 2018, L&C also was included in this shut down. The only thing that remains of L&C are the patents and IP that was assigned to Inspyr from the merger. Ironically the L&C website not too long ago re-emerged but has not been updated in a while! Check it out lncpharma.com